Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

Shares of Invitae (NYSE: NVTA) rose 13% last month, according to data provided by S&P Global Market Intelligence. There wasn't any specific news to spur shares higher, but investors and analysts have ...

The genetic testing company has been unprofitable as it spent heavily (but that’s only part of the story). For years I have detested the growth-at-all-costs business models followed by emerging growth ...

Invitae, a genetic testing services provider, reported Q1 2023 revenue of $117.4 million, down from Q1 2022's $123.7 million due to exited businesses and geographies. However, after accounting for ...

Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to ...

Shares of the genetic testing company have more than doubled in less than a week. It likely isn’t durable. It was also truly bizarre. Invitae announced a strategic pivot and provided financial ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...